Home Data and Automation GCN: AI analysis speeds FDA drug reviews

GCN: AI analysis speeds FDA drug reviews

“The use of an artificial intelligence-based platform to analyze forms is expected to save Food and Drug Administration reviewers of adverse drug report about 7,500 hours per year.” “ABBYY’s Digital Intelligence platform transforms as many as 120 fields in safety reports on potential adverse interactions during clinical drug trials into structured content that reviewers can […]

The post GCN: AI analysis speeds FDA drug reviews appeared first on FedHealthIT, a service of MileMarker10.

Leave a Reply